IMNN-001 immunotherapy plus standard-of-care chemotherapy resulted in 35% improvement in overall survival and 25% improvement in progression-free survival versus standard-of-care alone Treatment was ...

Ionis has announced the design for a Phase III trial of ION582, a treatment for Angelman syndrome (AS), following discussions with the FDA.

The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or ...

NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of the last patient last visit in ...

Bright Minds Biosciences' BMB-101 shows promise in treating drug-resistant epilepsy. Read why DRUG stock is a strong ...

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

PAR made substantial progress in its Phase 3 clinical trial preparations for the treatment of knee osteoarthritis (OA) with ...

The trial involves 54 patients in Switzerland and France, with completion anticipated in December 2029. The phase 2 INVINCIBLE-4 clinical trial is currently underway in patients with localized ...

In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...